Lupus nephritis: From pathogenesis to targets for biologic treatment by Liu, Yujuan & Anders, Hans-Joachim
E-Mail karger@karger.com
 Review 
 Nephron Clin Pract 2014;128:224–231 
 DOI: 10.1159/000368581 
 Lupus Nephritis: From Pathogenesis to 
Targets for Biologic Treatment 
 Yujuan Liu    Hans-Joachim Anders 
 Nephrologisches Zentrum, Medizinische Klinik und Poliklinik IV, Klinikum der Universität, München, 
 Munich , Germany 
matory cytokines drive the inflammatory process that can 
cause kidney injury, scarring, and chronic kidney disease. 
 Conclusion: Systemic lupus is more a variable syndrome 
than a single disorder based on heterogeneous genetic vari-
ants and complex aberrant immune alterations. This makes 
it less likely that a single specific biological drug will be as 
efficient as currently used unselective immunosuppressive 
drugs. Autoantibody production and intrarenal immune 
complex formation are the hallmark of lupus nephritis. How-
ever, kidney injury and scarring also result from local ampli-
fication of tissue inflammation. Therefore, a combination of 
unselective immunosuppressive and biological drugs that 
block immune cell recruitment or proinflammatory cyto-
kines may be promising to improve disease outcomes in lu-
pus nephritis.  © 2014 S. Karger AG, Basel 
 Introduction 
 Biological drugs have significantly improved out-
comes in many autoimmune disorders, but so far clini-
cal trials have failed to demonstrate any significant ben-
efit of biological drugs in lupus nephritis. This is surpris-
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 Abstract 
 Background/Aims: Lupus nephritis is an organ manifesta-
tion of systemic autoimmunity. Current treatment algo-
rithms are still based on unselective immunosuppressive 
drugs. There is hope that highly selective biological drugs 
could be as or even more effective but less toxic. A profound 
understanding of the pathogenesis of lupus nephritis is nec-
essary to identify the optimal molecular targets.  Methods: 
PubMed and www.clincialtrials.gov were searched using ‘lu-
pus nephritis’ as the key word.  Results: The pathogenesis of 
lupus nephritis is based (1) on the mechanisms that lead to 
loss of tolerance against nuclear autoantigens, i.e. systemic 
lupus, and then (2) on the mechanisms of immune complex-
induced intrarenal inflammation. Systemic lupus develops 
when genetic variants allow autoimmunization against nu-
clear autoantigens, e.g. by impairing lymphocyte depletion 
via apoptosis, opsonization, and rapid phagocytic clearance. 
This allows endogenous nucleic acids to directly activate 
Toll-like receptors on dendritic cells or B cells, a process that 
drives IFN-α-driven immunity, antigen presentation, and 
the activation of autoreactive lymphocyte subsets. Activa-
tion of B cells and their maturation to plasma cells promotes 
autoantibody production and subsequent immune complex 
glomerulonephritis. Complement and numerous proinflam-
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ing because all autoimmune disorders, including 
systemic lupus erythematosus (SLE), are based on anti-
gen-presenting cells that trigger the activation and pro-
liferation of autoreactive lymphocyte subsets. So what 
distinguishes the pathogenesis of SLE from other auto-
immune disorders? Why do clinical trials often fail to 
validate drug efficacy previously demonstrated in pre-
clinical experiments or uncontrolled cohort studies? 
Disease heterogeneity is an important factor that distin-
guishes SLE from other autoimmune disorders and 
which remains a challenge for clinical trial design. Ge-
nome-wide association studies have documented that 
numerous different genetic alterations, each of them 
conferring only a minor risk contribution, are present in 
SLE patients. This implies that SLE is rather a clinical 
syndrome that develops from different combinations of 
genetic alterations that cause systemic autoimmunity 
through different avenues of immune dysregulation. 
This may explain why some but not all patients benefit 
from biological drugs that modulate highly selective tar-
gets. Nonetheless, to move beyond unselective immuno-
suppressive drugs in lupus nephritis management, it is 
necessary to identify common pathways in the patho-
genesis of SLE and lupus nephritis. In this review, we 
briefly summarize current concepts of disease patho-
genesis in SLE and lupus nephritis and present molecu-
lar and cellular targets for biological drugs to improve 
disease outcomes.
 Pathogenesis of SLE and Lupus Nephritis 
 As we have recently described the current pathogenic 
concepts of SLE and lupus nephritis in detail elsewhere 
 [1] , only a brief summary is provided here ( table 1 ).
 Systemic Autoimmunity in SLE 
 SLE develops from a loss-of-tolerance for nuclear au-
toantigens as is evident from the presence of antinuclear 
antibodies. As tolerance against cell nuclei is normally as-
sured by numerous mechanisms and genes, many differ-
ent combinations of genetic and environmental factors 
can break tolerance, cause antinuclear antibody positivi-
ty, and eventually trigger SLE. The major checkpoints of 
immune dysregulation are described in  table 1 and below.
 Impaired Silent Cell Death and Dead Cell Removal. Ge-
netic variants that impair physiological (immunological-
ly silent) suicide of autoreactive lymphocytes during neg-
ative selection in lymphoid organs drive secondary ne-
crosis and the release of nuclear material into the 
extracellular space. Similarly, this is also the case with en-
vironmentally induced tissue cell necrosis, e.g. a sunburn 
or a trauma increases the amount of extracellular nuclear 
material. In SLE, often genetic variants that impair the 
phagocytic clearance of such extracellular nuclear parti-
cles keep nuclear particles in the extracellular space  [2] . 
For example, insufficient phagocytic clearance of extra-
cellular neutrophil traps contributes to this phenomenon 
 [3] .
 Nuclear Particles Trigger Antiviral Immunity via In-
nate Viral Recognition Receptors.  Extracellular nuclear 
particles share structural and molecular similarities with 
viral particles and their nucleic acid components can ac-
tivate dendritic cells and B cells via Toll-like receptors 7 
and 9  [4] . This specifically triggers the induction of 
interferon-α and subsequently a ‘pseudo’ antiviral im-
mune response, which accounts for unspecific symptoms 
of SLE including fatigue, fever, myalgia, and arthralgia 
 [5] .
 Autovaccination Leads to Persistent Antinuclear Anti-
body Production.  Because nuclear autoantigens are pre-
 Table 1.  Pathomechanisms in SLE and lupus nephritis
Pathomechanisms of autoimmunity outside the kidney
Impaired silent cell death and dead cell removal
Nuclear particles mimic viruses at viral recognition receptors of the innate immune system
Antiviral immunity
Autovaccination leading to persistent antinuclear antibody production
Flares triggered by transient autoantigen loads or unspecific immune activation
Pathomechanisms of lupus nephritis inside the kidney
Immune complex formation and classical complement pathway activation
Mesangial vs. subendothelial vs. subepithelial immune complexes
Intrarenal induction of cytokines, chemokines, and adhesion molecules recruits leukocytes
Tertiary lymphoid organ formation inside the kidney, i.e. local immunoglobulin production
Insufficient regeneration and tissue scarring 
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sented in the context of innate immune activation, in-
duced costimulation promotes the activation of T and B 
cell subsets with specificities for nuclear autoantigens. 
This process involves B cell maturation and differentia-
tion into plasma cells that produce antinuclear antibod-
ies. Memory T cells and bone marrow long-lived plasma 
cells assure lifelong immune memory, which cannot be 
eradicated by standard therapies conceptually like im-
mune memory obtained by previous vaccinations  [6] . 
Unspecific lymphoproliferation drives lymphadenopa-
thy as a manifestation of SLE.
 Incident Cell Necrosis or Unspecific Immune Activation 
Trigger SLE Flares.  Sudden massive cell death (sunburn 
or trauma) or exposure to immunostimulatory agents 
(e.g. during infections) mimic antigen re-exposure or 
provide unspecific stimuli of innate and adaptive immu-
nity that may expand autoreactive lymphocyte clones and 
cause a SLE flare  [7] .
 Intrarenal Pathomechanisms of SLE-Related Nephritis 
 Immune Complex Formation and Classical Comple-
ment Pathway Activation.  Lupus nephritis does not de-
velop in the absence of antinuclear antibodies  [8] . Circu-
lating polyclonal autoantibodies bind to intrarenal nu-
cleosomes and other autoantigens, which leads to local 
complement activation, cell injury, and subsequent cyto-
kine and chemokine secretion.
 The Immune Complex Formation Site Determines Lu-
pus Nephritis Outcomes.  The polyclonal lupus autoanti-
body isotypes can localize to different compartments 
within the glomerulus, which affects the type of histo-
pathological lesion as well as the alterations of glomerular 
function  [9] . Immune complex formation in the mesan-
gium induces mesangioproliferative glomerulonephritis 
(lupus nephritis classes I and II), which is often mild and 
rarely progresses to end-stage kidney disease. Subendo-
thelial immune complex formation (lupus nephritis 
classes III and IV) causes vascular obstruction by endo-
thelial cell swelling and clotting, which promotes a de-
cline of glomerular filtration rate. Vascular necrosis and 
glomerular basement membrane ruptures promote he-
maturia, crescent formation, and subsequently glomeru-
losclerosis. Subepithelial immune complex formation 
(membranous lupus nephritis class V) injures podocytes, 
which promotes massive proteinuria and podocyte loss-
related glomerulosclerosis.
 Induction of Cytokines, Chemokines, and Adhesion 
Molecules Recruits Leukocytes.  Leukocyte recruitment 
amplifies intrarenal inflammation and promotes second-
ary tissue injury related to tissue inflammation and drives 
a vicious cycle of inflammation-induced tissue injury and 
injury-related inflammation. To target this pathomecha-
nism, anti-inflammatory drugs that do not cause global 
immunosuppression may be sufficient.
 Tertiary Lymphoid Organ Formation inside the Kid-
ney. Local expression of lymphotoxin and homeostatic 
chemokines drives tertiary lymphoid organ formation at 
sites of chronic inflammation to promote the (auto-) im-
mune response, e.g. by local autoantibody production.
 Insufficient Regeneration and Tissue Scarring.  At-
tempts to heal tissue injury often create new lesions. Le-
sions of hyperactive repair include hyperproliferation of 
mesangial cells (mesangioproliferative lupus nephritis), 
endothelial cells (endocapillary lupus nephritis), and pa-
rietal epithelial cells (crescentic lupus nephritis). Lesions 
of insufficient repair include podocyte loss-related scar-
ring (FSGS and glomerulosclerosis).
 Therapeutic Targets for (Biological) Drugs 
 The current management of lupus nephritis remains 
based on steroids, cyclophosphamide, azathioprine, and 
mycophenolate mofetil, which are all unselective immu-
nosuppressive drugs that suppress multiple components 
of adaptive immunity  [10] . These drugs have proven to 
be efficient in reducing lupus nephritis disease activity, 
but the long-term outcomes of lupus nephritis have not 
further improved during the last 30 years. Unselective im-
munosuppressive drugs are associated with potentially 
life-threatening infectious complications. Therefore, it 
remains an unmet medical need to develop new drugs 
that more specifically interfere with the pathomecha-
nisms of SLE and cause less side effects  [11] . In the fol-
lowing we discuss several targets of interest and provide 
the rationale to explore them for the treatment of lupus 
nephritis (fig. 1). Past or ongoing clinical trials with tar-
get-related drugs are listed in  table 2 .
 Aberrant Cell Death and Insufficient Clearance of 
Dead Cells 
 Currently no biological drugs are available that spe-
cifically control this aspect of lupus pathogenesis. The 
prevention of sunburns by avoiding UV light exposure 
and using sunscreen remains important.
 Immunostimulatory Effects of Endogenous Nucleic 
Acids and IFN-α-Mediated Immunity 
 Toll-like receptor 7/9 blockade can suppress nucleic 
acid autoadjuvant-driven disease activity of lupus nephri-
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 Table 2.  Biological drugs for lupus nephritis listed in www.clinicaltrials.gov
Target Drug name Trial phase Trial status Duration,
months
Nephritis class NCT number
CD20 rituximab 2 completed 
results not published
12 III, IV, V NCT00556192
rituximab 3 completed 
results published
12 III, IV NCT00282347
rituximab 3 not yet recruiting 24 III, IV, V NCT01673295
rituximab 3 not yet recruiting 12 III, IV, V NCT01773616
rituximab 3 ongoing 24 active lupus nephritis NCT01765842
ocrelizumab 3 ongoing 12 III, IV NCT00626197
CD22 epratuzumab 1 completed 
results published
1 active lupus nephritis NCT00011908
CD74 milatuzumab 2 not yet recruiting 24 not specified NCT01845740
BLyS/BAFF belimumab 3 ongoing 24 active lupus nephritis NCT01639339
blisibimod 3 not yet recruiting 12 stable nephritis NCT02074020
CTLA4 abatacept 1 completed 
results published
2 SLE NCT00705367
abatacept 1/2A completed 
results not published
3 III, IV, V NCT00094380
abatacept 2 ongoing 12 SLE NCT00774852
abatacept 3 ongoing 12 III, IV NCT01714817
CD40L Bg9588 2 completed 
results published
5 III, IV NCT00001789
TWEAK BIIB023 2 ongoing 12 III, IV, V NCT01499355
BIIB023 2 ongoing 24 III, IV, V NCT01930890
IL-6 CNTO136 2 completed 
results not published
6 III, IV NCT01273389
MRA 1 completed 
results not published
3 moderately active lupus NCT00046774
IFN-γ AMG811 1 ongoing 6 III, IV NCT00818948
 Fig. 1. Pathomechanisms and treatment targets in lupus nephritis. 
 a Genetic variants of homeostatic lymphocyte death and of the 
rapid clearance of dead cells predispose to necrotic cell death and 
a persistence of nuclear particles in the extracellular space. No 
specific treatments are available at present for this aspect of lupus 
pathogenesis. The avoidance of sun burns and toxin exposure can 
help to prevent disease flares triggered by incident episodes of 
massive cell death.  b Extracellular nuclear particles containing au-
toadjuvants like CpG-DNA or immunostimulatory RNA together 
with other Toll-like receptor ligands released by dead cells acti-
vate antigen-presenting cells (dendritic cells and B cells) to pres-
ent autoantigens together with costimulatory molecules. This 
process leads to an immune interpretation of the autoantigen as 
‘foreign’ and triggers an adaptive immune response, e.g. autoan-
tigen-specific T and B cells. Several biological drugs intend to in-
terfere with this pathomechanism.  c Circulating autoantibodies 
bind to their respective autoantigens within the kidney, a process 
referred to as in situ immune complex formation. This activates 
complement and other inflammatory mediators that can be tar-
geted with biological drugs to control renal inflammation. IFN-γ, 
MHCI, MHCII (major histocompatibility complex), TNF, and 
BAFF/BLyS. (For figure see next page.)
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tis  [12, 13] , but the respective antagonists that are to be 
tested in clinical trials are more based on nucleic acid for-
mats than biological drugs. In contrast, the anti-IFN-α 
antibody sifalimumab was reported to meet the primary 
composite endpoint in a phase 2b trial of nonrenal lupus 
patients. Data on its efficacy on lupus nephritis are not yet 
available.
 Autoantigen Presentation and T Cell Activation 
 The processing and presentation of autoantigens in 
the context of costimulation is at the center of every au-
toimmune disease pathogenesis. Using CTLA-4-Ig to 
block the interaction between CD80 and CD86 on anti-
gen-presenting cells and CD28 on T cells efficiently sup-
presses alloimmune T cell activation after kidney trans-
plantation. However, abatacept failed to succeed to reach 
the primary endpoint in a randomized trial on the induc-
tion phase of lupus nephritis classes III and IV, although 
abatacept therapy had some effects on plasma levels of 
dsDNA autoantibodies and complement recovery  [14] . 
CD40 and CD40L also promote costimulation, but three 
trials with anti-CD40L failed to demonstrate efficacy. 
Abetimus is a drug that modulates autoimmunity via an-
tigen recognition by T cells. Abetimus is composed of a 
series of linked oligonucleotides, which block the binding 
of anti-dsDNA antibodies to their autoimmune targets 
and tolerize B cells with antigen-specificity for DNA. Un-
fortunately, the results in clinical trials have been very 
modest. The concept of anti-dsDNA-specific therapeutic 
interventions does not seem very promising as they target 
only a very small subset of autoreactive B cells in SLE. 
Antigen presentation requires peptide processing and 
loading into HLA molecules, a process that involves a 
nonredundant role for cathepsin S, the inhibition of 
which suppresses IgG autoantibody production and pre-
vents lupus nephritis in animal models  [15] . 
 B Cells and Short-Lived Plasma Cells 
 B cells clearly contribute to SLE and lupus nephritis, 
which provides a rationale for the use of drugs that de-
plete CD20+ B cells and short-lived plasma cells such as 
rituximab, ocrelizumab, or ofatumumab. Uncontrolled 
studies on refractory lupus nephritis documented re-
sponse rates of 75%  [16] , but the randomized placebo-
controlled LUNAR trial could not demonstrate any ben-
efit of add-on rituximab on top of a profound immuno-
suppressive regimen for the induction therapy of incident 
lupus nephritis classes III–V  [17] . However, the clinical 
efficacy of off-label rituximab use by many centers has 
maintained the interest in B cell ablation in lupus nephri-
tis. Based on uncontrolled efficacy data of rituximab 
monotherapy after methylprednisolone pulsing, the 
RITUXILUP trial will further test the concept of B cell 
ablation controlling severe lupus nephritis  [18] . CD22 is 
a 135-kDa B cell-specific transmembrane sialoglycopro-
tein that is expressed at the cell surface on mature IgM+ 
IgD+ B cells, but absent on plasma cells and memory B 
cells. Blocking CD22 with epratuzumab depletes naïve 
and transitional B cells via antibody-dependent cellular 
cytotoxicity, which lowers peripheral B cell counts by 
40%. This effect can improve moderate-to-severe nonre-
nal flares in SLE patients, but efficacy data on lupus ne-
phritis are not yet available  [19] . BLyS (B lymphocyte 
stimulator) is a B cell survival factor that can be blocked 
with belimumab. Large randomized placebo-controlled 
trials have proven that add-on belimumab on top of stan-
dard maintenance therapy can significantly reduce per-
sistent SLE activity  [20] , which has led to FDA and EMA 
approval of belimumab for the maintenance therapy of 
nonrenal lupus in the USA and Europe. Severe lupus ne-
phritis patients were excluded in the BLISS-56 and 
BLISS-76 trials, but data from patients with moderate ne-
phritis raise hope that belimumab can also be efficient in 
severe lupus nephritis  [21] . Such a trial is currently re-
cruiting patients. Other B cell-directed biological drugs 
include the recombinant TACI-human IgG fusion pro-
tein atacicept, the BAFF-blocking antibody LY2127399, 
and a BAFF-receptor antibody  [22] .
 Long-Lived Plasma Cells 
 Targeting long-lived plasma cells offers the potential 
of directly modulating antibody-producing cells that 
maintain humoral immune memory  [6] . These cells re-
side in survival niches in the bone marrow and in tertiary 
lymphoid organs within the inflamed tissue. They can be 
targeted by antithymocyte globulin, small molecule pro-
teasome inhibitors, anti-CD138/CD38 antibodies, or by 
targeting BLIMP-1. Data from clinical trials that have 
tested related biological drugs in lupus nephritis are not 
yet available  [6] .
 Mediators of Tissue Inflammation 
 Tissue inflammation involves numerous proinflam-
matory cytokines, some of which can now be targeted 
with biological drugs: TNF-α (infliximab), IL-6 (tocili-
zumab), IL-12 (ustekinumab), IL-17 (ixekizumab and 
secukinumab), and TWEAK (BIIB023). TNF blockade 
with infliximab is able to improve severe lupus nephritis, 
but holds the risk of enhancing autoimmunity and pro-
moting severe infectious complications  [23] . The trans-
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continental ATLAS trial that tests TWEAK blockade in 
the remission phase of lupus nephritis is still ongoing. 
Macrophage-dependent inflammation is targeted by an-
timacrophage inhibitory factor IgG, for which a safety 
study in lupus nephritis patients has been completed. 
Also the CCL2-CCR2 axis is a promising target to limit 
macrophage-dependent inflammation. Preclinical exper-
iments suggest that adding a CCL2 inhibitor to a low dose 
of cyclophosphamide is as efficient as high-dose cyclo-
phosphamide, but avoids myelosuppression and lympho-
cyte ablation  [24] . A first trial documented a positive ef-
fect on proteinuria using bindarit as a blocker of this 
pathway  [25] .
 Summary 
 Lupus nephritis develops from extrarenal and intrare-
nal pathomechanisms. The extrarenal factors include 
complex combinations of genetic variants in numerous 
immune pathways that are different in each patient, 
which may affect success rates of very selective biological 
drugs in clinical trials. Therefore, treating lupus nephritis 
with a monotherapy of a selective biological drug should 
be challenging. Unselective immunosuppressive drugs 
may remain necessary to suppress the complex interplay 
of the numerous immune cell subsets that contribute to 
humoral and cellular autoimmunity in SLE. Lupus ne-
phritis, however, is a classic immune complex glomeru-
lonephritis involving complement-mediated renal in-
flammation, amplified by infiltrating leukocytes and 
driven by numerous proinflammatory cytokines. Inflam-
mation-related kidney injury and tissue remodeling cause 
renal dysfunction and chronic kidney disease in lupus. 
Therefore, anti-inflammatory biological drugs that limit 
tissue injury should be attractive combination partners 
for unselective immunosuppressive drugs that control 
systemic autoimmunity.
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